#Monoclonal Antibodies In Veterinary Health Market 2030 | Explore Tumblr posts and blogs

industryforecastnews · 7 months ago

Text

U.S. Veterinary Orthopedic Medicine Market Size, Share & Growth Analysis Report, 2030

U.S. Veterinary Orthopedic Medicine Market Growth & Trends

The U.S. veterinary orthopedic medicine market size is expected to reach USD 814.51 million by 2030, registering a CAGR of 7.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the increasing pet population, adoption of pet insurance, rising prevalence of diseases among animals, and advancements in veterinary medicine.

For instance, in October 2023, the FDA approved Librela (bedinvetmab injection), making it the first monoclonal antibody for treating osteoarthritis-related pain in dogs. In addition, in April 2022, American Regent Animal Health, a division of American Regent, Inc., received FDA approval to extend the shelf life of Adequan Canine and Adequan i.m. The expiration date for both products was increased from 24 months to 36 months from the date of manufacture.

Key players in the veterinary orthopedic medicine market are engaging in strategic initiatives like product launches, collaborations, and acquisitions to make their market presence more prominent, impelling market growth. In September 2022, Zoetis acquired Jurox, a private animal health company specializing in veterinary medicines for livestock and companion animals. The deal, finalized in August 2021, included Jurox's operations in Australia and regional offices in the U.S., Canada, and the UK. Such initiatives are anticipated to drive market growth.

For instance, in October 2023, Athersys, Inc. (ATHX), a cell therapy and regenerative medicine company, entered into a licensing agreement with Ardent Animal Health. With this move, Athersys, known for its work with MultiStem (invimestrocel) in critical care, entered the field of animal health. This collaboration with Ardent, a veterinary biotech firm specializing in regenerative medicine and cancer therapies for animals, highlights Athersys’ commitment to advancing veterinary care.

Some key impacts of the pandemic and respective lockdowns on the market include dampened growth, decreased sales, supply chain disruptions, and operational challenges. However, the pandemic also propelled concerns over animal health and welfare, strengthened the pet parent and animal bond, and increased pet adoption. Moreover, the market witnessed an improved medicalization rate, pet expenditure, and adoption of pet insurance.

Increasing pet humanization and improved diagnostic rates were other positive impacts of the COVID-19 pandemic on the veterinary sector. In 2021, the market recorded increased demand and sale of veterinary medicines, including orthopedic medicines. In 2022, other macroeconomic uncertainties, such as global recession and cost inflation, adversely impacted the business. However, as the underlying market drivers remain unchanged owing to an increasing prevalence of orthopedic disorders in dogs and horses, the market is estimated to grow notably over the forecast period.

Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/us-veterinary-orthopedic-medicine-market-report

U.S. Veterinary Orthopedic Medicine Market Report Highlights

Based on product, pharmaceuticals segment dominated the market, accounting for a share of 46.72% in 2023. Pharmaceutical treatments for orthopedic diseases in pets, such as Non-steroidal Anti-inflammatory Drugs (NSAIDs) and pain relievers, have been widely used and established as effective treatments for managing pain and inflammation. On the other hand, the viscosupplements segment is anticipated to grow at the fastest CAGR of 8.23% during the forecast period

Based on animal type, the market is segmented into dogs and horses. The dogs segment dominated the market, accounting for a share of 51.98% in 2023. It is also anticipated to grow at the fastest CAGR of 7.80% in the coming decade

Based on application, the osteoarthritis segment accounted for the largest share of 60.65% of the market in 2023. The other segment is expected to grow at the fastest CAGR of 9.39% over the forecast period

Based on route of administration, the market is segmented into injectable, oral, and others (e.g., topical). The injectable segment dominated the market, accounting for a share of 60.40% in 2023. The others (e.g., topical) segment is anticipated to grow at the fastest CAGR of 8.22% in the coming decade

On the basis of end-use, veterinary clinics & hospitals segment accounted for the largest share of 53.59% of the market in 2023. The other segment is expected to grow at the fastest CAGR of 8.68% over the forecast period

U.S. Veterinary Orthopedic Medicine Market Segmentation

Grand View Research has segmented the U.S. veterinary orthopedic medicine market based on product, animal type, application, route of administration, and end-use:

U.S. Veterinary Orthopedic Medicine Product Outlook (Revenue, USD Million, 2018 - 2030)

Biologics

Stem Cells

Platelet-Rich Plasma (PRP)

Other Biologics

Viscosupplements

Pharmaceuticals

Steroids

NSAIDS

Others

U.S. Veterinary Orthopedic Medicine Animal Type Outlook (Revenue, USD Million, 2018 - 2030)

Dogs

Small Breeds

Medium Breeds

Large Breeds

Horses

U.S. Veterinary Orthopedic Medicine Application Outlook (Revenue, USD Million; 2018 - 2030)

Osteoarthritis

Degenerative Joint Disease

Others

U.S. Veterinary Orthopedic Medicine Route Of Administration Outlook (Revenue, USD Million, 2018 - 2030)

Injectable

Intra-Muscular

Intra-Articular

Others

Oral

Others

U.S. Veterinary Orthopedic Medicine End-use Outlook (Revenue, USD Million, 2018 - 2030)

Veterinary Hospitals & Clinics

At-home

Others

List of Key Players in the U.S. Veterinary Orthopedic Medicine Market

Zoetis Services LLC

Ardent Animal Health, LLC

Enso Discoveries

VetStem, Inc.

Contura Vet

PetVivo Holdings, Inc.

T-Cyte Therepeutics

Boehringer Ingelheim International GmbH

Arthrex, Inc.

MEDREGO LLC

Nucleus ProVets

Daiichi Sankyo Company, Limited

Bimeda U.S.

Browse Full Report: https://www.grandviewresearch.com/industry-analysis/us-veterinary-orthopedic-medicine-market-report

#U.S. Veterinary Orthopedic Medicine Market #U.S. Veterinary Orthopedic Medicine Market Size #U.S. Veterinary Orthopedic Medicine Market Trends #U.S. Veterinary Orthopedic Medicine Market Growth #U.S. Veterinary Orthopedic Medicine Market Sales

0 notes

rohit0024 · 2 years ago

Text

Monoclonal Antibodies In Veterinary Health Market Worth $2.67 Billion By 2030

Monoclonal Antibodies In Veterinary Health Market Growth & Trends The global monoclonal antibodies in veterinary health market size is expected to reach USD 2.67 billion by 2030 expanding at a CAGR of 16.7% from 2022 to 2030, according to a new report by Grand View Research, Inc. Increasing pet population coupled with the rising pet expenditure is expected to boost the market growth.…

View On WordPress

0 notes

businessinfinity · 2 years ago

Text

0 notes

petnews2day · 2 years ago

Text

The Worldwide Monoclonal Antibodies in Veterinary Health Industry is Expected to Reach $2.6 Billion by 2030

New Post has been published on https://petnews2day.com/pet-industry-news/pet-insurance-news/the-worldwide-monoclonal-antibodies-in-veterinary-health-industry-is-expected-to-reach-2-6-billion-by-2030/

The Worldwide Monoclonal Antibodies in Veterinary Health Industry is Expected to Reach $2.6 Billion by 2030

Company Logo

Monoclonal Antibodies in Veterinary Health Market

Dublin, Nov. 08, 2022 (GLOBE NEWSWIRE) — The “Monoclonal Antibodies in Veterinary Health Market Share, Size, Trends, Industry Analysis Report, By Animal Type, By Application, By End-Use, By Region, Segment Forecast, 2022 – 2030” report has been added to ResearchAndMarkets.com’s offering.

According to this new study, the global monoclonal antibodies in veterinary health market size is expected to reach USD 2,629.6 million by 2030. The report gives a detailed insight into current market dynamics and provides an analysis of future market growth.

The industry is expanding due to the development of novel monoclonal antibodies and increasing the cost of pets, treatments for allergic conditions, and increasing incidences of cancer, especially in dogs. Additionally, it is anticipated that awareness of advanced veterinary therapeutic options is likely to complement market growth.

The main drivers for market growth are the rising prevalence of atopic dermatitis and the rising rate of pet adoption. Additionally, the growing demand for therapeutic antibodies for the treatment of dogs’ allergy diseases also contributes to the industry expansion.

The COVID-19 lockdowns and supply chain disruptions had less of an impact on the animal health industry economy than on other industries. In contrast, traditional practices generate a majority of their revenues from selling their high-margin products, such as pharmaceuticals.

Monoclonal Antibodies In Veterinary Health Market Report Highlights

Based on the animal type, dogs segment generated the largest share in 2021. The rising acceptance of pet insurance due to the increasing prevalence of numerous chronic diseases in animals is one of the major factors driving industry expansion

The prevalence of dermatological conditions such as allergic dermatitis and flea-and-tick-related disorders is predicted to rise. Some of the most often diagnosed dermatological diseases include seborrheic dermatitis, surface pyoderma, allergies, and otitis externa.

North America accounted for the largest revenue share in 2021. This is due to a number of initiatives from the public and private sectors, as well as the growing acceptance of pet insurance. Key industry participants in these regions are contributing to the revenue expansion.

Some of the major players operating in the global industry adivo GmbH ink, Bayer Animal Health, Boehringer Ingelheim GmbH, Elanco; Indian Immunologicals Ltd, Invetx, Kindred Biosciences, Inc., Merck & Co. Inc, Nextmune, Virbac, Zoetis

Story continues

Key Topics Covered:

1. Introduction

2. Executive Summary

3. Research Methodology

4. Global Monoclonal Antibodies in Veterinary Health Market Insights 4.1. Monoclonal Antibodies in Veterinary Health – Industry Snapshot 4.2. Monoclonal Antibodies in Veterinary Health Market Dynamics 4.2.1. Drivers and Opportunities 4.2.1.1. Rising pet owner concerns and expanding pet insurance 4.2.1.2. Rising importance of therapeutic monoclonal antibodies 4.2.2. Restraints and Challenges 4.2.2.1. Increase in the cost of pet healthcare 4.3. Porter’s Five Forces Analysis 4.3.1. Bargaining Power of Suppliers (Moderate) 4.3.2. Threats of New Entrants: (Low) 4.3.3. Bargaining Power of Buyers (Moderate) 4.3.4. Threat of Substitute (Moderate) 4.3.5. Rivalry among existing firms (High) 4.4. PESTEL Analysis 4.5. Monoclonal Antibodies in Veterinary Health Market Industry Trends 4.6. Value Chain Analysis 4.7. COVID-19 Impact Analysis

5. Global Monoclonal Antibodies in Veterinary Health Market, by Animal Type 5.1. Key Findings 5.2. Introduction 5.2.1. Global Monoclonal Antibodies in Veterinary Health Market, by Animal Type, 2018 – 2030 (USD Million) 5.3. Dogs 5.3.1. Global Monoclonal Antibodies in Veterinary Health Market, by Dogs, by Region, 2018 – 2030 (USD Million) 5.4. Others 5.4.1. Global Other Monoclonal Antibodies in Veterinary Health Market, by Region, 2018 – 2030 (USD Million)

6. Global Monoclonal Antibodies in Veterinary Health Market, by Application 6.1. Key Findings 6.2. Introduction 6.2.1. Global Monoclonal Antibodies in Veterinary Health Market, by Application, 2018 – 2030 (USD Million) 6.3. Dermatology 6.3.1. Global Monoclonal Antibodies in Veterinary Health Market, by Dermatology, by Region, 2018 – 2030 (USD Million) 6.4. Pain 6.4.1. Global Monoclonal Antibodies in Veterinary Health Market, by Pain, by Region, 2018 – 2030 (USD Million) 6.5. Others 6.5.1. Global Monoclonal Antibodies in Veterinary Health Market, by Others, by Region, 2018 – 2030 (USD Million)

7. Global Monoclonal Antibodies in Veterinary Health Market, by End-Use 7.1. Key Findings 7.2. Introduction 7.2.1. Global Monoclonal Antibodies in Veterinary Health Market, by End-Use, 2018 – 2030 (USD Million) 7.3. Veterinary Hospitals 7.3.1. Global Monoclonal Antibodies in Veterinary Health Market, by Veterinary Hospitals, by Region, 2018 – 2030 (USD Million) 7.4. Others 7.4.1. Global Other Monoclonal Antibodies in Veterinary Health Market, by Region, 2018 – 2030 (USD Million)

8. Global Monoclonal Antibodies in Veterinary Health Market, by Geography

9. Competitive Landscape 9.1. Expansion and Acquisition Analysis 9.1.1. Expansion 9.1.2. Acquisitions 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles 10.1. adivo GmbH 10.1.1. Company Overview 10.1.2. Financial Performance 10.1.3. Product Benchmarking 10.1.4. Recent Development 10.2. Bayer Animal Health 10.2.1. Company Overview 10.2.2. Financial Performance 10.2.3. Product Benchmarking 10.2.4. Recent Development 10.3. Boehringer Ingelheim GmbH 10.3.1. Company Overview 10.3.2. Financial Performance 10.3.3. Product Benchmarking 10.3.4. Recent Development 10.4. Elanco 10.4.1. Company Overview 10.4.2. Financial Performance 10.4.3. Product Benchmarking 10.4.4. Recent Development 10.5. Indian Immunologicals Ltd 10.5.1. Company Overview 10.5.2. Financial Performance 10.5.3. Product Benchmarking 10.5.4. Recent Development 10.6. Invetx 10.6.1. Company Overview 10.6.2. Financial Performance 10.6.3. Product Benchmarking 10.6.4. Recent Development 10.7. Kindred Biosciences, Inc 10.7.1. Company Overview 10.7.2. Financial Performance 10.7.3. Product Benchmarking 10.7.4. Recent Development 10.8. Merck & Co. Inc 10.8.1. Company Overview 10.8.2. Financial Performance 10.8.3. Product Benchmarking 10.8.4. Recent Development 10.9. Nextmune 10.9.1. Company Overview 10.9.2. Financial Performance 10.9.3. Product Benchmarking 10.9.4. Recent Development 10.10. Virbac 10.10.1. Company Overview 10.10.2. Financial Performance 10.10.3. Product Benchmarking 10.10.4. Recent Development 10.11. Zoetis 10.11.1. Company Overview 10.11.2. Financial Performance 10.11.3. Product Benchmarking 10.11.4. Recent Development

For more information about this report visit https://www.researchandmarkets.com/r/3mkj0p

Attachment

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

#Pet Insurance News

0 notes

tmr123123 · 3 years ago

Text

Animal Vaccine Market Overview, Merger and Acquisitions , Drivers, Restraints and Industry Forecast By 2030

Market Overview:

The Global Animal Vaccine market was valued at USD 7.85 billion by 2020, growing with 5.89% CAGR during the forecast period, 2021-2030.

Animals are vaccinated to prevent various diseases. Vaccines may contain living or dead bacterial substances, inactivated viral substances, or attenuated viral substances. There are also vaccines, called toxicities that provide protection against pathogenic toxins produced by bacteria. The Animal vaccines can be given by injection, as a spray into the nostrils, or by mouth. Animal vaccines can be segmented as bacterins composed of inactivated bacterial inocula, toxicoid drugs made up of inactivated toxins , Antitoxins and antiserum contain antibodies that can fight toxins or even the germ , Polyclonal and monoclonal antibodies contain antibodies specific to a variety of infections and work by providing antibodies which provide an additional source of resistance that will help reduce the impact of impending disease.

Animal vaccine plays an essential role in health and in the prevention of zoonoses, diseases that can be transmitted between humans and animals. Globalization exposes humans to diseases that spread across borders, through travel and trade which propelled the global animal vaccine market growth. Vaccines play an essential role in preventing these risks by protecting animal health, food safety and public health.

Click Here to Get Sample Premium Report @https://www.trendsmarketresearch.com/report/sample/13658

Market Dynamics and Factors:

In the worldwide animal vaccine market share, North America share generated the most revenue. This is due to increased adoption of pets, increased consumption of meat and milk, and increased understanding of the benefits of utilising animal vaccinations. Due to an increase in companion animals and a growth in the prevalence of various diseases, Asia-Pacific has a significant market potential that might influence animal vaccines market trends. Furthermore, due to the rising demand for animal-based food items and companion animals, continuing research on new vaccine manufacturing technologies has grown. Furthermore, increased investment in animal healthcare firms has enhanced the creation of novel medicines

Increased livestock epidemics, expanding livestock population, and rising frequency of zoonotic illnesses are driving the worldwide veterinary animal vaccines market expansion. Rising public knowledge of commercial vaccinations is to blame for the global increase in adoption. This industry is one of the attractive investment options vying for attention and investment from both non-government and government important players.

Other key factors driving animal vaccine market expansion include a shift in emphasis towards healthy animal husbandry and an increase in the number of pet owners. The government's engagement in channel distribution has an impact on total profitability. In June 2021 at G7 Summit meeting UK Prime minister Boris Johnson announced that UK will produce & develop new vaccines for livestock, to curb the spread of diseases which may mutate and cross to humans

You can Buy This Report from Here @https://www.trendsmarketresearch.com/checkout/13658/Single

Market Segmentation:

Global animal vaccine can be segmented on the basis of By Livestock Animal Vaccine Type (Bovine Vaccines, Poultry Vaccines, Porcine Vaccines, Other Livestock Vaccines),By Companion Animal Vaccine type (Canine Vaccines, Feline Vaccines, Equine Vaccines),By Technology (DNA Vaccine, Live Attenuated Vaccines, Subunit Vaccines, Inactivated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Other Technologies) By Market Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa).

Geographic Analysis:

During the projected period, the Asia Pacific veterinary vaccines market is predicted to develop at the fastest rate in the veterinary vaccines industry, Asia Pacific is anticipated to develop at the fastest rate. Rising pet adoption, expansion of leading vaccine manufacturers, increased product availability, and investments in production facilities in different Asia Pacific nations, particularly India, China, and Thailand, are the primary drivers driving the growth of this market.

Request For Report Discounts @https://www.trendsmarketresearch.com/report/discount/13658

Competitive Scenario:

The animal vaccine market, which is highly competitive, consists of a few major players. The key players of Animal Vaccine market are Merck& Co., Inc., Zoetis, Vaxxinova, Boehringer Ingelheim International GmbH, Colorado Serum Company, Biovac, Pfizer, BiogénesisBagó,, Indian Immunologicals Ltd., Elanco, Romvac, Arko Laboratories, Ceva, Phibro Animal Health Corporation, Neogen Corporation, Intas Pharmaceuticals Ltd.

0 notes

healthcare-market · 3 years ago

Text

Closed System Transfer Devices [CSTD] Market Will Escalate Rapidly in the Near Future

Closed System Transfer Devices (CSTD) Market: Introduction

According to the report, the global closed system transfer devices (CSTD) market was valued at US$ 764.7 Mn in 2019 and is projected to reach US$ 2.4 Bn by 2030, expanding at a CAGR of ~11% from 2020 to 2030. Closed system transfer devices (CSTDs) are used to transfer medication from one reservoir to another, while limiting the potential for drug aerosolization, drug contamination, sharps exposure, and hazardous drug exposure. The closed drug reconstitution and transfer system components allow safe reconstitution of liquid or pre?dissolved powder drugs into infusion bags, flexible bottles, or syringes. Single, partial, or multiple vials can be used for each infusion solution container. Components of CSTD system are vial adaptors, syringe adaptors, spike port adaptor, connecting set, Luer lock adaptor, and tubing sets & accessories. These products have shorter lifespan and are primarily single-use products.

Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=55230

Closed System Transfer Devices (CSTD) Market Dynamics

In terms of product, the global closed system transfer devices (CSTD) market has been divided into systems (needle free systems and needle systems), component (vial adaptors and syringe adaptors), tubing sets and accessories. New closed system transfer devices are easy to operate and integrate into practice, are designed to reduce waste, help make implementations easier, and reduce confusion. These factors are expected to drive the segment. Based on application, the global closed system transfer devices (CSTD) market has been categorized into pharmacy, nursing, and veterinary. Increase in awareness to avoid occupational exposure to drugs and availability of new closed system transfer devices in hospital pharmacies are likely to drive the pharmacy segment during the forecast period.

Request for Analysis of COVID19 Impact on Closed System Transfer Devices [CSTD] Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=55230

Pharmaceuticals and biotechnology are large components of the healthcare system. Prices of drugs continue to rise every year, especially intravenous antineoplastic agents, cytotoxic antibiotics, alkylating drugs, and monoclonal antibodies. In 2017, the global sales of oncology-related medications stood at around US$ 133 Bn, with nearly US$ 50 Bn sales in the U.S. Devices such as closed system transfer devices increase the lifeline of drugs by preserving the sterility of single use medication vials for up to at least 1 week by preventing contamination. According to the U.S. Pharmacopeia Chapter 797 (USP 797), single-use vials should be used within six hours of opening, if maintained in an International Organization for Standardization (ISO) 5 environment.

Request a Sample of Closed System Transfer Devices [CSTD] Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=55230

North America to Dominate Global Market

The global closed system transfer devices (CSTD) market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for major share of the global closed system transfer devices (CSTD) market in 2019. Exposure to hazardous drugs can result in adverse health effects in healthcare workers. Hence, increase in exposure of healthcare workers to hazardous drugs at the workplace is likely fuel the growth of the market in North America. According to the Centers for Diseases Control and Prevention, nearly 8 million healthcare workers in North America are potentially exposed to hazardous drugs.

China is likely to be a highly lucrative market for closed system transfer devices (CSTD) during the forecast period. Rise in the target population requiring treatment in developed regions and higher utilization of CSTDs are expected to drive the global closed system transfer devices (CSTD) market during the forecast period.

Purchase Closed System Transfer Devices [CSTD] Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=55230&ltype=S

Competition Landscape

ICU Medical, Inc., Baxter International, Inc., B. Braun Melsungen AG, and Equashield LLC are the three major companies operating in the global closed system transfer devices (CSTD) market. The global closed system transfer devices (CSTD) market is fragmented in terms of number of players. Key players in the global market include ICU Medical, Inc., Baxter International, Inc., B. Braun Melsungen AG, Becton, Dickinson and Company, Equashield LLC, Corvida Medical, Yukon Medical, Caragen Ltd., and JMS Co. Ltd.

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants, uses proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research, 90 State Street, Suite 700, Albany, NY 12207 Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Website: https://www.transparencymarketresearch.com/

0 notes

rohit0024 · 2 years ago

Text

Monoclonal Antibodies In Veterinary Health Market Worth $2.67 Billion By 2030

View On WordPress

0 notes

rohit0024 · 2 years ago

Text

Monoclonal Antibodies In Veterinary Health Market Worth $2.67 Billion By 2030

View On WordPress

0 notes

rohit0024 · 2 years ago

Text

Monoclonal Antibodies In Veterinary Health Market Worth $2.67 Billion By 2030

View On WordPress

0 notes

petnews2day · 2 years ago

Text

The Worldwide Monoclonal Antibodies in Veterinary Health Industry is Expected to Reach $2.6 Billion by 2030

New Post has been published on https://petnews2day.com/pet-industry-news/pet-insurance-news/the-worldwide-monoclonal-antibodies-in-veterinary-health-industry-is-expected-to-reach-2-6-billion-by-2030/

The Worldwide Monoclonal Antibodies in Veterinary Health Industry is Expected to Reach $2.6 Billion by 2030

Company Logo

Monoclonal Antibodies in Veterinary Health Market

Monoclonal Antibodies In Veterinary Health Market Report Highlights

Story continues

Key Topics Covered:

1. Introduction

2. Executive Summary

3. Research Methodology

8. Global Monoclonal Antibodies in Veterinary Health Market, by Geography

9. Competitive Landscape 9.1. Expansion and Acquisition Analysis 9.1.1. Expansion 9.1.2. Acquisitions 9.2. Partnerships/Collaborations/Agreements/Exhibitions

For more information about this report visit https://www.researchandmarkets.com/r/3mkj0p

Attachment

#Pet Insurance News

0 notes